A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RG-012 for Injection in Subjects With Alport Syndrome
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2018
At a glance
- Drugs RG 012 (Primary)
- Indications Hereditary nephritis
- Focus Adverse reactions; Proof of concept
- Acronyms HERA
- Sponsors Regulus Therapeutics
- 07 Mar 2018 According to a Regulus Therapeutics media release, company will complete enrollment in the second half of 2018.
- 03 Nov 2017 Status changed from active, no longer recruiting to recruiting.
- 22 Oct 2017 Planned End Date changed from 1 Feb 2018 to 1 Nov 2019.